Eero Kajantie
During the last two decades, a considerable body of evidence has emerged showing that circumstances during the fetal period and childhood may have lifelong programming effects on different body functions with a considerable impact on disease susceptibility …
Konstantinos A. Toulis, Athanasios D. Anastasilakis, Stergios A. Polyzos, Polyzois Makras
Targeting osteoblast may be the means of effectively improving both bone quality and mass, thus offering an intriguing alternative in the treatment of osteoporosis. Aside from injectable parathyroid hormone (PTH) and its novel preparations, PTH-related peptide (PTHrP), calcilytics …
Athanasios N. Tsartsalis, Charalambos Dokos, Georgia D. Kaiafa, Dimitris N. Tsartsalis, Antonios Kattamis, Apostolos I. Hatzitolios, Christos G. Savopoulos
Osteoporosis is a major health problem affecting both men and women. Statins, besides their action as lipid-lowering agents, seem to have additional pleiotropic properties, among them a beneficial effect on bone mineral density. The entirety of experimental and the majority of clinical studies …
Ioannis P. Stathopoulos, Efstathios G. Ballas, Kalliopi Lampropoulou-Adamidou, George Trovas
While osteoporosis has been traditionally considered as a disease of aging women, it is becoming an increasingly important male health problem, with one in three fragility fractures after the age of 50 years occurring in men …
Ioannis Ilias, Salvatore Alesci, Philip W. Gold, George P. Chrousos
The longer life expectancy of women than that of men and, therefore, the longer exposure to fracture risk has, at least partially, led to neglect of osteoporosis in men. Recently, unipolar depression, which is 2 times more frequent in women than in men, has been linked to osteoporosis…
Stefano Stagi, Chiara Iurato, Elisabetta Lapi, Loredana Cavalli, Maria Luisa Brandi, Maurizio de Martino
More and more data seem to indicate the presence of an increasing number of syndromes and genetic diseases characterized by impaired bone mass and quality. Meanwhile, the improvement of etiopathogenetic knowledge and the employment of more adequate treatments have generated a significant increase …
Peter D. Papapetrou
The adverse events of the nitrogen-containing bisphosphonates are reviewed. Oral bisphosphonates (alendronate, risedronate and ibandronate), mainly used for the treatment of osteoporosis, have been associated with adverse events from the upper gastrointestinal tract …
Konstantinos Ziambaras, Roberto Civitelli, Stathis S. Papavasiliou
As human beings venture into space in the 21st century, they will be confronted with a “hypodynamic” and thus hostile environment for the bone homeostasis, that could potentially compromise their mobility in general and skeletal strength in particular after landing. From this point of view, space flight studies are especially interesting and intriguing models for scientists…
Kyriakos Aloumanis, Kostantinos Mavroudis
Osteoporosis and depression are two chronic diseases that affect large population groups with great impact on morbidity, mortality and quality of life. An association between osteoporosis and depression has been described in the literature …
Mauro Doga, Stefania Bonadonna, Andrea Giustina
Chronic exposure to excessive concentrations of endogenous cortisol or to pharmacologic doses of glucocorticoids (GCs) causes multiple deleterious effects on body structure and function. Osteopenia, osteoporosis and bone fractures are well recognized consequences of excessive GC exposure, with fractures being a major cause of morbidity and mortality, particularly in the elderly. In particular, GCs have profound effects on bone metabolism, acting at many sites…
Stefano Stagi, Cristina Manoni, Perla Scalini, Francesco Chiarelli, Alberto Verrotti, Cecilia Cecchi, Elisabetta Lapi, Sabrina Giglio, Silvia Romano, Maurizio de Martino
OBJECTIVE: To evaluate bone mineral status and metabolism in a cohort of patients with Williams-Beuren syndrome (WBS). PATIENTS: Thirty-one children (15 females, 16 males; mean age 9.6±2.74 years) and 10 young adults (6 females, 4 males; mean age 21.4±5.11 years) with WBS were cross-sectionally evaluated and compared with two age-, sex-, and body-size-matched paediatric …
Zhanna E. Belaya, Galina A. Melnichenko, Ljudmila Y. Rozhinskaya, Valentin V. Fadeev, Tatjana M. Alekseeva, Olga K. Dorofeeva, Natalja I. Sasonova, Galina S. Kolesnikova
OBJECTIVE: To evaluate the effects of subclinical hyperthyroidism of variable etiology on bone mineral density (BMD) and bone metabolism in postmenopausal women. DESIGN: T he study included data of 88 postmenopausal women classified into four groups depending on the etiology of subclinical hyperthyroidism: (1) 20 with toxic multinodular goiter without history of clinical hyperthyroidism …
Konstantinos Toulis, Paschalia Iliadou, Stylianos Mandanas, Polyzo Kazila, Efterpi Margaritidou, Konstantinos Georgopoulos, Kalliopi Pazaitou-Panayiotou
Along with achieving a reduction in the incidence of osteoporotic fractures, denosumab (a human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL) causes conformational changes in the calcium-sensing receptor (CaSR), leading to parathyroid hormone exocytosis …
Shizhang Liu, Zhi Yi, Ming Ling, Jiyuan Shi
OBJECTIVE: Osteoporosis is a serious and common health issue of considerable complexity among postmenopausal women. The osteoprotegerin gene (OPG) is considered to play an important role in the pathogenesis of osteoporosis. The objective of this study was to detect single nucleotide polymorphisms …
Polyzois Makras, Antonios Galanos, Stavroula Rizou, Athanasios D. Anastasilakis, George P. Lyritis
OBJECTIVE: This article describes the development and validation of the osteoporosis treatment questionnaire (OSTREQ), which is a physician-reported outcome tool aiming to evaluate physicians’ criteria in the choice of osteoporosis treatment. DESIGN: The questionnaire –named OSTREQ– consisting of 17 questions that were divided into eight sections …
Athanasios D. Anastasilakis, Dimitrios G. Goulis, Marina Kita, Avraam Avramidis
OBJECTIVE: Bisphosphonates are potent antiresorptive agents used for a spectrum of metabolic bone diseases. The aim of this study was to compare the adverse effects (AEs) of alendronate, etidronate and risedronate prescribed in a non-selected population, attending a single institution on an outpatient basis…
Athanasios Christoforidis, Eirini Kazantzidou, Ioanna Tsatra, Haido Tsantali, George Koliakos, Emmanouil Hatzipantelis, George Katzos, Miranda Athanassiou-Metaxa
OBJECTIVE: Osteopenia/osteoporosis of multi-factorial pathogenetic mechanism is reported to be a significant cause of morbidity in adult patients with β-thalassaemia major. Even in young patients, decreased Bone Mineral Density (BMD) values are a consistent finding in the literature. This study was performed in order to assess BMD …
Maria Andrikoula, Amalia Sertedaki, Sofia Andrikoula, Catherine Dacou-Voutetakis, Agathocles Tsatsoulis
PROP-1 gene mutations have been reported as a cause of combined pituitary hormone deficiency. Physical and hormonal phenotypes of affected individuals are variable. We report a 63-year-old female who presented with osteoporosis
Kalliopi Lampropoulou-Adamidou, George Trovas, Ioannis P. Stathopoulos, Nikolaos A. Papaioannou
OBJECTIVE: Pregnancy- and lactation-associated osteoporosis (PLO) is an uncommon disease. The majority of cases are seen in the third trimester or early post-partum in primagravid women and the prominent clinical feature of PLO is severe and prolonged back pain and height loss. The prevalence and aetiology of this disorder …
Labrini Papanastasiou, Stelios Fountoulakis, Nikos Voulgaris, Theodora Kounadi, Theodosia Choreftaki, Akrivi Kostopoulou, George Zografos, Charalampos Lyssikatos, Constantine A. Stratakis, George Piaditis
OBJECTIVE: Carney complex (CNC) is a rare autosomal dominant multiple neoplasia syndrome characterized by the presence of endocrine and non-endocrine tumors. More than 125 different germline mutations of the protein Kinase A type 1-α regulatory subunit (PRKAR1A) gene have been reported. We present a novel PRKAR1A gene germline mutation in a patient with severe osteoporosis and recurrent vertebral fractures. DESIGN: Clinical case report …